Published online before print May 6, 2004, doi: 10.1161/01.RES.0000131498.36194.6b
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 American Heart Association, Inc.
Molecular Medicine |
Vascular Endothelial Growth Factor Receptor-2–Induced Initial Endothelial Cell Migration Depends on the Presence of the Urokinase Receptor
From the Department of Vascular Biology and Thrombosis Research (G.W.P., J.M.B., S.S., D.O., J.M., P.M.B., B.R.B.), University of Vienna; K-plus competence centre for Bio Molecular Therapeutics, BMT (J.M.B., H.S., B.R.B.); and the Institute of Immunology (H.S.), Vienna International Research Cooperation Center at Novartis Forschungs-Institut, University of Vienna, Vienna, Austria.
Correspondence to Bernd R. Binder, Department of Vascular Biology and Thrombosis Research University of Vienna, Schwarzspanierstr. 17, Vienna A-1090, Austria. E-mail bernd.binder{at}univie.ac.at
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The angiogenic response of endothelial cells initiated by different growth factors is accompanied by assembly of cell surface–bound proteolytic machinery as a prerequisite for focal invasion. We have shown previously how the vascular endothelial growth factor (VEGF) initiates proteolysis by activation of pro-urokinase (pro-PA) via the VEGF receptor-2 (VEGFR-2). We now show that the cell surface receptor of the uPA-system, the urokinase receptor (uPAR), is redistributed to focal adhesions at the leading edge of endothelial cells in response to VEGF. VEGF165 and VEGF-E, both interacting with VEGFR-2, but not PlGF exclusively stimulating VEGFR-1, induce within minutes internalization of uPAR via an LDL receptor–like molecule, dependent on generation of active uPA and the presence of plasminogen activator inhibitor-1 (PAI-1). uPAR seems to play a pivotal role in VEGFR-2–induced endothelial cell migration because cleavage of surface uPAR impaired the migratory response of endothelial cells toward VEGF-E, but not toward PlGF.
Key Words: angiogenesis • VEGF • urokinase receptor
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The angiogenic process induced by growth factors such as vascular endothelial growth factor (VEGF) involves several key steps, including endothelial cell activation, migration and invasion, proliferation, and finally capillary strand and tube formation.1 Endothelial cell invasion requires degradation and reorganization of extracellular matrix proteins. Therefore, cells have to elaborate a repertoire of proteolytic enzymes, whereby both serine proteases of the plasminogen/plasmin system and matrix metalloproteinases (MMPs) are thought to be important.1,2 To focus the proteolytic machinery toward the leading edge of invading cells, urokinase, the initial enzyme of this machinery, is bound to the cell surface via its GPI-anchored receptor, uPAR (CD87). In fact, it was shown that uPAR is found at the leading edge in invading cells3,4 and inhibition of functional activity of uPAR5,6 significantly decreases the invasive potential in several types of cells. In addition, uPAR-deficient mice show significantly reduced leukocyte recruitment to inflamed areas.7 In this context, it is, however, unclear how uPAR is redistributed to the focal adhesions in migrating cells.
During angiogenesis, endothelial cells have to invade the surrounding tissue and inhibition of the urokinase system leads to impaired angiogenesis. Furthermore, uPAR is found predominantly at invasive sites of capillary tubes.8 We have shown previously that VEGF165 induces activation of pro-uPA bound to its receptor uPAR,9 but it is not known which of the stimuli operative during angiogenesis drives uPAR into the leading edge and how this process is initiated. It was the aim of this study to analyze how uPAR is rearranged in endothelial cells on VEGF stimulation, to study how this process is initiated, and to examine possible consequences of uPAR redistribution for endothelial cell migration.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Cell Culture
For experiments, human skin microvascular (HUSMEC) or umbilical vein endothelial cells (HUVECs) were used under serum free conditions. For all key experiments, results obtained with HUVECs were confirmed in HUSMECs; the specific cell type shown in the figure is indicated in the respective figure legend. Murine microvascular ECs were isolated and characterized from the uterus of PAI-1–/– mice,10 and from the respective wild-type controls.
For further details, see the expanded Materials and Methods section in the online data supplement available at http://circres.ahajournals.org.
Cytofluorimetric Analysis
Monolayers of subconfluent ECs were treated as indicated, thereafter harvested and fixed, and aliquots were permeabilized. A monoclonal antibody against human or a polyclonal antibody against mouse uPAR and Alexa Fluor 488-conjugated secondary antibodies were used. Samples were analyzed with FACSort (Becton-Dickinson). Surface protein was calculated from geometric mean fluorescence values and expressed as percent of total fluorescence measured in permeabilized cells. At least three independent experiments were performed. Specific calculations used are given in the respective figure legends.
Immunocytochemistry
Human ECs were fixed and stained as described before.9 For double antigen staining, cells were simultaneously incubated with antibodies against uPAR and phospho-paxillin (pPax) for 2 hours at 37°C, washed and then incubated with a mixture of Alexa-488 labeled anti rabbit and Alexa-568 labeled anti-mouse antibodies for 1 hour, 37°C. Deconvolution microscopy was used for analysis of stained cells (see expanded Materials and Methods).
Antisense Oligonucleotides
Rhodamine-labeled phosphorothioate oligodeoxyribonucleotides (10 µmol/L) were freshly dissolved in PBS and added to HUSMECs. After two days of treatment, cells were stimulated with VEGF or left untreated. Cell surface uPAR was quantified by FACS-analysis as described earlier, gating rhodamine-red fluorescent events to analyze oligonucleotide-positive ECs. Efficiency of oligonucleotide uptake was verified by immunocytochemistry.
PI-PLC Sensitivity of uPAR Redistribution
105 ECs (incubated or treated as indicated) were washed and surface labeled with sulfo-NHS-SS-Biotin as described.11 Thereafter, they were treated either with 5 U/mL PI-PLC at 37°C for 15 minutes or with buffer as control, followed by gently washing. PI-PLC efficiency was assessed by FACS-analysis of cell surface uPAR.
Video-Based Migration Assay and In Vivo Matrigel Angiogenesis Assay
HUSMECs seeded on vitronectin-coated glass coverslips were stimulated as indicated for 4 hours. Therefore, the cover slips were mounted onto cell culture chambers on a heated stage insert on an Olympus AX-70 microscope for time-lapse-recording of cell migration for 4 hours, whereby 20 images per hour were recorded (F-View digital camera, Soft Imaging System). Recorded time-lapse sequences were analyzed by assessing the length of the track of every individual cell.
The effect of RAP on rm-VEGF164–induced in vivo angiogenesis was analyzed as described previously.12
Statistics
Statistical significance was determined by paired or unpaired t test when one group was compared with the control group. To compare 2 or more groups with the control group 1-way ANOVA and Dunnett tests as posttests were used. Significance was assigned to a value of P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
VEGF by Interacting With VEGFR-2, but Not by Interacting With VEGFR-1 Leads to Redistribution of uPAR
In an initial experiment, we analyzed the possible effects of VEGF165 on the overall distribution of uPAR in endothelial cells. After stimulation of endothelial cells with VEGF165, uPAR was rearranged to structures in the cell periphery and to the leading edges. There uPAR colocalized with phosphopaxillin (Figure 1A) and the focal adhesion kinase (not shown), indicating increased presence of uPAR after VEGF165 stimulation in focal adhesions. The number of focal adhesions increased on VEGF165 stimulation by
2.5 times, whereas the number of uPAR-positive focal adhesions increased 3.5 times (Figure 1B). Ninety out of 97 analyzed endothelial cells showed such an increase in uPAR-positive focal adhesions. To analyze which VEGF165 receptor is responsible for the observed VEGF effect on uPAR, we used PlGF (Figure 1C) and VEGF-E (Figure 1D), specific ligands for VEGFR-1 (flt-1) and VEGFR-2 (flk-1), respectively.13,14 Only VEGF-E caused uPAR redistribution, whereas PlGF did not. However, PlGF-treated cells exhibited focal adhesions comparable to VEGF165 or VEGF-E treatment. From these data, we conclude that VEGF165, when bound to its VEGFR-2, causes rapid uPAR redistribution to focal adhesions at the leading edges of endothelial cells.
|
VEGF-Induced uPAR Redistribution Involves an Internalization Mechanism
In order to investigate whether uPAR redistribution on VEGF165 stimulation involves internalization, we quantified the effects of VEGF165 on the distribution of uPAR by FACS analysis on permeabilized and nonpermeabilized cells. As shown in Figure 2, in unstimulated endothelial cells, 96% of total cell uPAR was found on the cell surface, whereas VEGF165 induced a decrease in cell surface uPAR already after 30 minutes leading to a maximal decrease of surface uPAR after two hours (70.3±5.2%, P<0.01 of total uPAR). The total amount of uPAR did not change during this initial time, consistent with previously published data2,15; uPAR protein expression started to increase after 4 hours with a maximum after 20 hours of VEGF165 stimulation (Figure 2C). This indicates that during the first four hours of VEGF165 stimulation, synthesis of uPAR protein does not affect uPAR surface distribution. In addition, uPAR internalization in response to VEGF165 stimulation was independent of the protein synthesis inhibitor cycloheximide (not shown). To further analyze if uPAR internalization is also restricted to VEGFR-2, we again used specific ligands for VEGFR-1 and VEGFR-2. Only VEGF-E induced a decrease in surface uPAR comparable to VEGF165, whereas PlGF was ineffective (Figure 2D). Therefore, we conclude that VEGF165 induces internalization and redistribution of uPAR via VEGFR-2.
|
VEGF165 Induces uPAR Internalization Dependent on Active Urokinase and a Member of the LDL Receptor Family
Two well-known processes are described for internalization of uPAR. One is dependent on formation of a ternary complex of uPAR with its specific ligand urokinase (uPA) and the specific plasminogen activator inhibitor-1 (PAI-1) that leads to internalization of the uPAR/uPA/PAI-1 complex to the endosomal compartment via a member of the LDL receptor family.16 This internalization is followed by recycling of unoccupied uPAR17 to the cell surface. The second mechanism is internalization of uPAR via binding to the cation-independent mannose 6-phosphate/insulin-like growth factor-II receptor (CIMPR).18,19 Endocytosis via the former mechanism is inhibited by the 39-kD receptor-associated protein (RAP),17 whereas the latter one is inhibited by a peptide derived from the interaction site of uPAR and CIMPR as described by us previously (Peptide B).20 As shown in Figure 3A and 3B, VEGF165-induced internalization of uPAR was blocked by the addition of 200 nmol/L RAP (P<0.01), whereas Peptide B (15 µmol/L) was ineffective, indicating an LDL-receptor family member–dependent mechanism.
|
Receptor-bound activated uPA is a prerequisite for complex formation with its inhibitor PAI-1 triggering binding of the uPAR complex to a member of the LDL-receptor family.16,17 When complex formation between uPA and PAI-1 was inhibited by the low molecular weight competitive uPA inhibitor benzamidine,21 no uptake of uPAR complexes occurred (Figure 3C). Because of the high PAI-1 synthesis in endothelial cells,22 the most effective way to assess participation of PAI-1 in such complex formation was to analyze endothelial cells derived from PAI-1–/– mice. Indeed, rmVEGF164 did not induce uPAR internalization in these cells as compared with the respective wild-type cells (Figure 3D). These data indicate that VEGF-induced uPAR internalization in endothelial cells is dependent on formation of a uPAR/uPA/PAI-1 complex and its binding to a member of the LDL-receptor family.
uPAR Internalization in Response to VEGF165 Is MMP-2 and MT1-MMP, PI3-Kinase, and Integrin Dependent
Urokinase is synthesized in its inactive precursor form pro-uPA, which binds to its receptor uPAR. To form complexes with its inhibitor PAI-1, pro-uPA has to become activated. Previously, we could demonstrate that VEGF165 stimulation of endothelial cells activates pro-uPA when bound to its receptor uPAR via a mechanism, which requires a PI3-kinase–dependent change in conformation of integrin ß1 as well as active MMP-2.9 In order to analyze if uPAR internalization is a consequence of VEGF165-induced pro-uPA activation, we used a set of experiments that interfered with the step of pro-uPA activation9 and analyzed uPAR internalization.
First, we used 1,10-phenanthroline, a broad inhibitor of MMPs, and the specific MMP-2 inhibitor [(2R)-2-[(4-Biphenylylsulfonyl)amino]-3-phenylpropionic acid], both shown by us to prevent VEGF165-induced pro-uPA activation.9 In fact, these inhibitors were also capable to inhibit VEGF165-induced uPAR internalization, whereas specific inhibitors of other matrix-metalloproteinases were not (Figure 4A). Activation of pro-MMP-2 is readily achieved on the cell surface by membrane-type 1 matrix metalloproteinase (MT1-MMP), an MMP with a transmembrane domain.23 To test the involvement of MT1-MMP in our system, we used human MT1-MMP antisense oligonucleotides as they were used before by others.24 In addition, MMP-2 antisense oligonucleotides25 and respective scrambled oligonucleotides were used. In cells treated with MT1-MMP antisense as well as in those treated with MMP-2 antisense, VEGF165 had no effect on uPAR redistribution, whereas in cells treated with scrambled oligonucleotides VEGF165 was still effective with respect to uPAR internalization (Figure 4B).
|
VEGF165, when bound to its receptor VEGFR-2, activates among other signaling cascades, including MAP kinase p3826 and ERK-1/2 pathways,12 and also the PI3-kinase pathway, which leads to a change in integrin affinity,27 causing pro-uPA activation.9 Therefore, we studied the effects of respective inhibitors of signaling pathways originating from the VEGFR-2 on uPAR internalization and found that the PI3-kinase inhibitor wortmannin (100 nmol/L) and the PKA-inhibitor H-89 (20 µmol/L) prevented VEGF165-induced uPAR internalization (Figure 4C). When a possible effect of these inhibitors on VEGF165-induced pro-uPA activation was bypassed by the addition of active uPA in the presence or absence (not shown) of VEGF165, wortmannin was ineffective, whereas the PKA inhibitor H-89, known to inhibit the endocytotic process itself,28 prevented both VEGF165 and uPA-induced uPAR internalization. This indicates that H-89 acts on the endocytotic process, whereas wortmannin is effective upstream. Other pathway inhibitors (PD098059 and SB203580), which were already ineffective at the level of pro-uPA activation,9 were also ineffective at the level of uPAR internalization.
As further indication that VEGF165-induced pro-uPA activation is operative also in VEGF165-induced rapid uPAR redistribution, we determined the effects of VEGF165-induced changes in integrin affinity, shown previously by us to induce pro-uPA activation, on uPAR redistribution. Indeed, the divalent cation manganese that induces a strong conformation change of integrins29 abolished VEGF165-induced uPAR internalization (Figure 4D). In contrast, the soluble integrin ligand mimetic peptide (RGD-S, having a broad specificity for RGD-dependent integrins) by itself induced uPAR internalization and was additive with the VEGF165 effects on uPAR (Figure 4D). We also found that the MMP2/9 inhibitor abolished the effects of RGD, suggesting that uPAR internalization is brought about in similar ways by RGD and VEGF165 both being dependent on proteolysis of pro-uPA.
Therefore, in addition to the requirement of active uPA (Figure 3C) all mechanisms that prevented pro-uPA activation in response to VEGF1659 also prevented uPAR internalization, and we conclude that pro-uPA activation by VEGF165 is a prerequisite for uPAR internalization.
VEGF165-Induced uPAR Internalization Is Followed by Its Redistribution to Focal Adhesions
In order to analyze whether interference with uPAR internalization would also block uPAR rearrangement to focal adhesions, the presence of uPAR in focal adhesions on VEGF165 stimulation was followed in the presence of the MMP-2/9 inhibitor or RAP both shown to inhibit uPAR internalization (Figures 3A, 3B, and 4
A). The MMP-2/9 inhibitor as well as RAP largely impaired uPAR redistribution to focal adhesions (Figure 5A). In the presence of RAP or the MMP-2/9 inhibitor, the number of focal adhesions found after VEGF165 stimulation was decreased by 15% and 25%, respectively, and only 20% of these focal adhesions stained for uPAR as compared with 37±3% (mean±SD) uPAR-positive focal adhesions after treatment with VEGF165 alone. In non-VEGF165–stimulated endothelial cells, 27±6% (mean±SD) of focal adhesions were uPAR positive. These results suggest that on VEGF165 stimulation, internalized uPAR might be recycled back to the cell surface mainly to focal adhesions.
|
To test recycling of uPAR to focal adhesion, we labeled cell surface proteins with cleavable sulfo-NHS-SS-biotin, induced internalization of uPAR by stimulation with VEGF165 (30 minutes), removed remaining cell surface biotin label by treatment with glutathione (15 minutes at 4°C), and continued VEGF165 stimulation (90 minutes). Colocalization of internalized and recycled biotin surface label (green) with phospho-FAK (red) is shown in Figure 5B, top panel. When GPI-anchored surface proteins were removed from the cell surface by treatment with PI-PLC before the initial VEGF165 stimulation, colocalization was reduced to 54%. When GPI-anchored surface proteins were removed from the cell surface by treatment with PI-PLC after the initial VEGF165 stimulation, biotinylated proteins again colocalized with phospho-FAK (Figure 5B, bottom). A monoclonal anti-uPAR antibody was used to prove the presence of uPAR among the biotinylated proteins colocalizing with phospho-FAK in these experiments (not shown). Therefore, we conclude that uPAR in focal adhesions mainly originates from uPAR originally internalized and then recycled back to focal adhesions.
uPAR Internalization and Redistribution Contributes to the Migratory Response Toward VEGFR-2
Having shown that VEGF165 induces uPAR internalization and redistribution dependent on pro-uPA activation, uPAR/uPA/PAI-1 complex formation and the interaction with an LRP-like molecule, we were interested if this sequence of events has a biological significance. One major cellular phenomenon, in which uPAR-dependent proteolytic activity as well as the continuous formation of focal adhesions is required, is cell migration. VEGF initiates endothelial cell migration already within 1 hour after stimulation. We therefore analyzed whether depletion of uPAR itself would alter VEGF-induced endothelial cell migration. When we stimulated endothelial cells with VEGF-E or PlGF for 4 hours, we observed an increase in the migratory response for both growth factors (141±11% for VEGF-E and 125±3% for PlGF) (Figure 6A). After cleavage of the GPI-anchor of uPAR using PI-PLC, the migratory response toward VEGF-E was diminished (107±18%), whereas the migratory response toward PlGF was unaffected, consistent with the observation shown in Figure 1C that PlGF induces focal adhesion formation without any participation of uPAR. When internalization of the uPAR/uPA/PAI-1 complex was inhibited by RAP, the migratory response of endothelial cells toward VEGF165 was reduced by 70% (Figure 6B), indicating a biological significance for VEGF-induced uPAR internalization. Also in an in vivo endothelial cell migration assay using matrigel plugs,12 the number of invading cells on rm-VEGF164 stimulation was reduced by 68% when RAP was incorporated into such an assay (Figure 6C).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Growth factors and chemokines activate cells to migrate and invade surrounding tissues. For invasion, the coordinated formation of a localized proteolytic machinery is necessary. Focusing uPAR toward the leading edge of migrating cells provides such armor8 and inhibition of uPA binding to its receptor inhibits invasion of endothelial cells.5 It is not known, however, at which step of the invasive process redistribution of uPAR occurs and how it is achieved. We could show previously that VEGF165 interacting with its receptor VEGFR-2 rapidly induces pro-uPA activation that is dependent on a change in integrin affinity, on activation of MMP-2, and on pro-uPA being bound to its surface receptor uPAR.9 This VEGF-induced pro-uPA activation in endothelial cells is responsible for VEGF-dependent fibrinolytic activity.9 In this study, we show that VEGF165 induces via the same mechanism also internalization of uPAR. This suggests that the initial step in this process is VEGF-induced pro-uPA activation followed by uptake of the uPAR/uPA/PAI-1 complex by an LDL-receptor like molecule. Although we have no direct evidence that formation of the trimolecular complex is a prerequisite for uPAR internalization, data obtained from PAI-1–/– cells indicate that uPAR internalization in response to VEGF is PAI-1 dependent. Thus, initially receptor-bound pro-uPA needs to become activated in order to form a complex with PAI-1 that is taken up in an LDL receptor–like molecule dependent fashion. uPAR internalization itself was originally described by others,16,30 but VEGF-induced uPAR internalization is shown for the first time in this study. Consistent with this model, we found that in case of VEGF-induced uPAR internalization a uPA inhibitor could inhibit VEGF-induced uPAR internalization. An alternate mechanism of internalization of uPAR via the mannose 6-phosphate/insulin-like growth factor-II receptor (CIMPR) was also described by others18 and us,19,20 but because respective inhibitory peptides derived from CIMPR were ineffective in our system, we can exclude participation of CIMPR in VEGF-induced uPAR internalization. Taken together our data indicate that VEGF induces uPAR internalization by initially activating pro-uPA followed by complex formation with PAI-1 and interaction of the ternary complex uPAR/uPA/PAI-1 with a member of the LDL receptor–like family.
During endothelial cell migration, uPAR is redistributed to focal adhesions on the leading edge. Such redistribution can occur either by lateral movement or by internalization and recycling of the receptor. In this study, we provide evidence that in endothelial cells on VEGF stimulation, redistribution of uPAR occurs mainly via recycling of the endocytosed receptor. This is shown by focal adhesions largely devoid of uPAR when they are formed on VEGF stimulation under conditions where uPAR internalization is inhibited. We clearly could show this phenomenon for MMP-2/9 inhibitor–treated cells, in which receptor-bound pro-uPA activation9 as well as uPAR internalization were inhibited. We also found a significant percentage of focal adhesions lacking uPAR despite VEGF stimulation in cells where uPAR internalization was inhibited by RAP. Because under these experimental conditions few focal adhesions still exhibit uPAR staining, contribution of other cellular events to the reduction of uPAR in focal adhesions cannot be excluded. Therefore, in another set of experiments, we labeled surface proteins of endothelial cells with glutathione cleavable biotin. When internalization of uPAR by VEGF was induced in these cells and remaining surface label was removed by treatment with glutathione, surface-labeled proteins appeared in focal adhesions and colocalized with uPAR. When GPI-anchored proteins, which include uPAR, were removed from the surface after labeling, significantly less surface label appeared in focal adhesions after VEGF stimulation, indicating that GPI-linked proteins are recycled to the leading edges. These data suggest that on VEGF stimulation of endothelial cells pro-uPA activation leads not only to uPAR internalization, but also to a controlled recycling of uPAR to focal adhesions at the leading edge.
uPAR redistribution seems to participate in endothelial cell migration induced by VEGFR-2 because cleavage of the GPI-anchor diminished the migratory response significantly, whereas PlGF-induced endothelial cell migration was not affected by uPAR cleavage. This indicates that different growth factors induce different migratory pathways. The migratory response and the respective involved pathways might depend also on the matrix that supports migration. The effects shown in this study were observed using a vitronectin matrix. Our data, showing that RAP that inhibits internalization of uPAR/uPA/PAI-1 complex also inhibits endothelial cell migration ex vivo on a matrigel matrix and in a matrigel plug assay in vivo, further indicate that uPAR internalization and in turn relocalization to focal adhesions is a general important part of the VEGF-R–induced endothelial cell response. From these data, it is also obvious that the mechanism described not only provides the necessary proteolytic potential at the leading edge for invasion, but it is also important for migration itself. This pathway is clearly not the only one operative in endothelial cells, because PlGF interacting with VEGFR-1 does neither cause pro-uPA activation9 nor uPAR internalization and redistribution, but still induces migration independent of the presence of uPAR.
|
Acknowledgments |
|---|
This work was supported in part by grants from the Austrian Science Foundation (SFB 5-09 to B.R.B. and SFB 5-03 to H.S.) and by the EU 6th Framework Integrated Project Cancerdegradome (LSHC-CT-2003-503297).
|
Footnotes |
|---|
*Both authors contributed equally to this study.
Original received December 30, 2003; revision received April 22, 2004; accepted April 27, 2004.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000; 6: 389–395.[CrossRef][Medline] [Order article via Infotrieve]
2. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol. 2001; 21: 1104–1117.
3. Cavallaro U, Wu Z, Di Palo A, Montesano R, Pepper MS, Maier JA, Soria MR. FGF-2 stimulates migration of Kaposi’s sarcoma-like vascular cells by HGF-dependent relocalization of the urokinase receptor. FASEB J. 1998; 12: 1027–1034.
4. Dumler I, Weis A, Mayboroda OA, Maasch C, Jerke U, Haller H, Gulba DC. The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J Biol Chem. 1998; 273: 315–321.
5. Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 1996; 56: 2428–2433.
6. Ossowski L. Effect of antisense inhibition of Urokinase receptor on malignancy. Curr Top Microbiol Immunol. 1996; 213: 101–112.[Medline] [Order article via Infotrieve]
7. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med. 1998; 188: 1029–1037.
8. Kroon ME, Koolwijk P, van Goor H, Weidle UH, Collen A, van der PG, van Hinsbergh VW. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices. Am J Pathol. 1999; 154: 1731–1742.
9. Prager GW, Breuss JM, Steurer S, Mihaly J, Binder BR. Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood. 2004; 103: 955–962.
10. Carmeliet P, Kieckens L, Schoonjans L, Ream B, van Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan RC. Plasminogen activator inhibitor-1 gene-deficient mice, I: generation by homologous recombination and characterization. J Clin Invest. 1993; 92: 2746–2755.[Medline] [Order article via Infotrieve]
11. Weaver AM, McCabe M, Kim I, Allietta MM, Gonias SL. Epidermal growth factor and platelet-derived growth factor-BB induce a stable increase in the activity of low density lipoprotein receptor-related protein in vascular smooth muscle cells by altering receptor distribution and recycling. J Biol Chem. 1996; 271: 24894–24900.
12. Lucerna M, Mechtcheriakova D, Kadl A, Schabbauer G, Schafer R, Gruber F, Koshelnick Y, Muller HD, Issbrucker K, Clauss M, Binder BR, Hofer E. NAB2, a corepressor of EGR-1, inhibits vascular endothelial growth factor-mediated gene induction and angiogenic responses of endothelial cells. J Biol Chem. 2003; 278: 11433–11440.
13. Christinger HW, Fuh G, De Vos AM, Wiesmann C. The crystal structure of PlGF in complex with domain 2 of VEGFR1. J Biol Chem. 2004; 279: 10382–10388
14. Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Buttner M, Rziha HJ, Dehio C. A novel vascular endothelial growth factor encoded by Orf virus, VEGF- E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 1999; 18: 363–374.[CrossRef][Medline] [Order article via Infotrieve]
15. Koolwijk P, van Erck MG, de Vree WJ, Vermeer MA, Weich HA, Hanemaaijer R, van Hinsbergh VW. Cooperative effect of TNF
, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol. 1996; 132: 1177–1188.
16. Herz J, Clouthier DE, Hammer RE. LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell. 1992; 71: 411–421.[CrossRef][Medline] [Order article via Infotrieve]
17. Nykjaer A, Conese M, Christensen EI, Olson D, Cremona O, Gliemann J, Blasi F. Recycling of the urokinase receptor upon internalization of the uPA: serpin complexes. EMBO J. 1997; 16: 2610–2620.[CrossRef][Medline] [Order article via Infotrieve]
18. Nykjaer A, Christensen EI, Vorum H, Hager H, Petersen CM, Roigaard H, Min HY, Vilhardt F, Moller LB, Kornfeld S, Gliemann J. Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J Cell Biol. 1998; 141: 815–828.
19. Godar S, Horejsi V, Weidle UH, Binder BR, Hansmann C, Stockinger H. M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-beta1. Eur J Immunol. 1999; 29: 1004–1013.[CrossRef][Medline] [Order article via Infotrieve]
20. Leksa V, Godar S, Cebecauer M, Hilgert I, Breuss J, Weidle UH, Horejsi V, Binder BR, Stockinger H. The N-terminus of mannose 6-phosphate/Insulin-like growth factor 2 receptor in regulation of fibrinolysis and cell migration. J Biol Chem. 2002; 277: 40575–40582.
21. Huber K, Kirchheimer J, Binder BR. Rapid isolation of high molecular weight urokinase from native human urine. Thromb Haemost. 1982; 47: 197–202.[Medline] [Order article via Infotrieve]
22. Zoellner H, Hofler M, Beckmann R, Bielek E, Vanyek E, Kumabashiri I, Binder B. Fibrinolytic proteins in apoptotic human umbilical vein endothelial cells. Thromb Res. 1998; 91: 209–219.[CrossRef][Medline] [Order article via Infotrieve]
23. Atkinson SJ, Crabbe T, Cowell S, Ward RV, Butler MJ, Sato H, Seiki M, Reynolds JJ, Murphy G. Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes. J Biol Chem. 1995; 270: 30479–30485.
24. Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol. 2000; 148: 615–624.
25. Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamvakopoulos G, Moses MA. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A. 2000; 97: 3884–3889.
26. Mechtcheriakova D, Schabbauer G, Lucerna M, Clauss M, De Martin R, Binder BR, Hofer E. Specificity, diversity, and convergence in VEGF and TNF- signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J. 2001; 15: 230–242.
27. Podar K, Tai YT, Lin BK, Narsimhan RP, Sattler M, Kijima T, Salgia R, Gupta D, Chauhan D, Anderson KC. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with ß1 integrin- and phosphatidylinositol 3-kinase-dependent PKC activation. J Biol Chem. 2002; 277: 7875–7881.
28. Goretzki L, Mueller BM. Receptor-mediated endocytosis of urokinase-type plasminogen activator is regulated by cAMP-dependent protein kinase. J Cell Sci. 1997; 110: 1395–1402.[Abstract]
29. Takagi J, Petre B, Walz T, Springer T. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell. 2002 ;110: 599.[Medline] [Order article via Infotrieve]
30. Conese M, Olson D, Blasi F. Protease nexin-1-urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and 2- macroglobulin receptor. J Biol Chem. 1994; 269: 17886–17892.
This article has been cited by other articles:
 |
|
 |
|
  Y. Jing, C. Tong, J. Zhang, T. Nakamura, I. Iankov, S. J. Russell, and J. R. Merchan Tumor and Vascular Targeting of a Novel Oncolytic Measles Virus Retargeted against the Urokinase Receptor Cancer Res., February 15, 2009; 69(4): 1459 - 1468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Prager, J. Mihaly, P. M. Brunner, Y. Koshelnick, G. Hoyer-Hansen, and B. R. Binder Urokinase mediates endothelial cell survival via induction of the X-linked inhibitor of apoptosis protein Blood, February 5, 2009; 113(6): 1383 - 1390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. B. Schiller, A. Szekeres, B. R. Binder, H. Stockinger, and V. Leksa Mannose 6-Phosphate/Insulin-like Growth Factor 2 Receptor Limits Cell Invasion by Controlling {alpha}V{beta}3 Integrin Expression and Proteolytic Processing of Urokinase-type Plasminogen Activator Receptor Mol. Biol. Cell, February 1, 2009; 20(3): 745 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liu, D. J. Cao, I. M. Sainz, Y.-L. Guo, and R. W. Colman The inhibitory effect of HKa in endothelial cell tube formation is mediated by disrupting the uPA-uPAR complex and inhibiting its signaling and internalization Am J Physiol Cell Physiol, July 1, 2008; 295(1): C257 - C267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. W.M. van Hinsbergh, M. A. Engelse, and P. H.A. Quax Pericellular Proteases in Angiogenesis and Vasculogenesis Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 716 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Bauer, W. Liu, F. Fan, E. R. Camp, A. Yang, R. J. Somcio, C. D. Bucana, J. Callahan, G. C. Parry, D. B. Evans, et al. Targeting of Urokinase Plasminogen Activator Receptor in Human Pancreatic Carcinoma Cells Inhibits c-Met- and Insulin-like Growth Factor-I Receptor-Mediated Migration and Invasion and Orthotopic Tumor Growth in Mice Cancer Res., September 1, 2005; 65(17): 7775 - 7781. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||